Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Bayer faces U.S. antitrust hurdles for Monsanto merger: Bloomberg

Published 03/15/2018, 01:08 PM
Updated 03/15/2018, 01:10 PM
© Reuters.  Bayer faces U.S. antitrust hurdles for Monsanto merger: Bloomberg

(Reuters) - Bayer (DE:BAYGN) AG's plan to win antitrust approval to buy U.S. seeds supplier Monsanto (NYSE:MON) Co has not satisfied U.S. officials, who are worried the $62.5 billion merger could hurt competition, Bloomberg reported on Thursday.

Shares of Monsanto fell 4 percent in heavy afternoon trading following the news.

The U.S. Department of Justice wants Bayer to divest more assets to satisfy its conditions, and does not think the German chemicals company's current proposal is sufficient, Bloomberg reported, citing people familiar with the matter.

Monsanto spokeswoman Sara Miller declined to comment. A Bayer spokesman said the company would not comment on rumors, but added it remains in talks with regulators to help close the deal in the second quarter of the year.

Bayer had pledged to sell certain seed and herbicide assets for 5.9 billion euros ($7.26 billion) to BASF to address EU regulatory concerns and has separately offered to sell its vegetable seeds business to BASF. [nL5N1QP3ET]

The company has secured an approval from Brazilian regulators for the merger, while it is in the frame to win conditional antitrust approval from the European Union, Reuters reported this week. [nL3N1QV4EG]

Bayer also has conditional approval from China's commerce ministry.

($1 = 0.8121 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.